Blinatumomab is a bispecific construct that reacts simultaneously to normal CD3⁺ T cells and CD19⁺ ALL cells, creating a tight intercellular connection followed by T-cell–mediated cytotoxicity exerted on CD19⁺ blast cells (bispecific T-cell engaging [BiTE] mechanism).⁹  Professional illustration by Paulette Dennis.